Hengehold Capital Management LLC boosted its stake in shares of Johnson & Johnson (NYSE:JNJ) by 4.5% in the third quarter, HoldingsChannel reports. The firm owned 14,037 shares of the company’s stock after purchasing an additional 599 shares during the quarter. Hengehold Capital Management LLC’s holdings in Johnson & Johnson were worth $2,090,000 as of its most recent filing with the Securities and Exchange Commission (SEC).
Other institutional investors and hedge funds have also recently bought and sold shares of the company. Newfound Research LLC acquired a new position in Johnson & Johnson in the third quarter valued at about $28,000. Islay Capital Management LLC bought a new stake in shares of Johnson & Johnson during the second quarter worth about $42,000. FAI Wealth Management grew its holdings in shares of Johnson & Johnson by 45.9% during the second quarter. FAI Wealth Management now owns 321 shares of the company’s stock worth $45,000 after purchasing an additional 101 shares during the last quarter. SeaBridge Investment Advisors LLC boosted its holdings in Johnson & Johnson by 160.0% in the second quarter. SeaBridge Investment Advisors LLC now owns 325 shares of the company’s stock valued at $46,000 after acquiring an additional 200 shares during the last quarter. Finally, HWG Holdings LP bought a new stake in Johnson & Johnson in the second quarter valued at approximately $49,000. 67.44% of the stock is owned by institutional investors.
Several brokerages have issued reports on JNJ. Cantor Fitzgerald boosted their price target on Johnson & Johnson from $168.00 to $180.00 and gave the company an “overweight” rating in a research note on Wednesday, October 14th. Credit Suisse Group increased their price target on Johnson & Johnson from $163.00 to $168.00 and gave the company an “outperform” rating in a research report on Wednesday, October 14th. Stifel Nicolaus lowered Johnson & Johnson from a “buy” rating to a “hold” rating in a research report on Wednesday, August 19th. ValuEngine upgraded Johnson & Johnson from a “sell” rating to a “hold” rating in a research note on Monday, August 3rd. Finally, Raymond James restated a “buy” rating on shares of Johnson & Johnson in a research note on Friday. One analyst has rated the stock with a sell rating, four have given a hold rating and ten have issued a buy rating to the stock. The stock currently has an average rating of “Buy” and a consensus price target of $164.93.
Shares of NYSE:JNJ opened at $146.36 on Friday. The stock has a fifty day simple moving average of $145.51 and a two-hundred day simple moving average of $146.57. The stock has a market capitalization of $385.30 billion, a price-to-earnings ratio of 23.01, a PEG ratio of 3.04 and a beta of 0.69. Johnson & Johnson has a 12-month low of $109.16 and a 12-month high of $157.00. The company has a current ratio of 1.48, a quick ratio of 1.24 and a debt-to-equity ratio of 0.51.
Johnson & Johnson (NYSE:JNJ) last announced its quarterly earnings data on Sunday, October 18th. The company reported $2.20 earnings per share (EPS) for the quarter, beating the Zacks’ consensus estimate of $1.98 by $0.22. Johnson & Johnson had a return on equity of 34.64% and a net margin of 21.01%. The business had revenue of $21.08 billion during the quarter, compared to analysts’ expectations of $20.15 billion. During the same quarter in the previous year, the business earned $2.12 earnings per share. The firm’s quarterly revenue was up 1.7% compared to the same quarter last year. As a group, equities research analysts predict that Johnson & Johnson will post 7.99 EPS for the current year.
The firm also recently declared a quarterly dividend, which will be paid on Tuesday, December 8th. Stockholders of record on Tuesday, November 24th will be paid a $1.01 dividend. This represents a $4.04 annualized dividend and a dividend yield of 2.76%. The ex-dividend date is Monday, November 23rd. Johnson & Johnson’s dividend payout ratio is currently 46.54%.
In other news, EVP Kathryn E. Wengel sold 16,115 shares of the business’s stock in a transaction on Wednesday, September 2nd. The stock was sold at an average price of $153.52, for a total value of $2,473,974.80. Following the completion of the transaction, the executive vice president now owns 66,658 shares in the company, valued at $10,233,336.16. The transaction was disclosed in a document filed with the Securities & Exchange Commission, which can be accessed through the SEC website. 0.27% of the stock is owned by insiders.
Johnson & Johnson Profile
Johnson & Johnson researches and develops, manufactures, and sells various products in the health care field worldwide. It operates in three segments: Consumer, Pharmaceutical, and Medical Devices. The Consumer segment offers baby care products under the JOHNSON'S brand; oral care products under the LISTERINE brand; beauty products under the AVEENO, CLEAN & CLEAR, DR.
See Also: Correction
Want to see what other hedge funds are holding JNJ? Visit HoldingsChannel.com to get the latest 13F filings and insider trades for Johnson & Johnson (NYSE:JNJ).
Receive News & Ratings for Johnson & Johnson Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Johnson & Johnson and related companies with MarketBeat.com's FREE daily email newsletter.